Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects
Current Issues in Molecular Biology · 26.12.2024 · 47 (1) · 7
DOI: 10.3390/cimb47010007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 26.12.2024. Verfasst von Dileep G Nair und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital Aachen, D-52074 Aachen, Ge…. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Deutsche Krebshilfe, Interdisciplinary Centre for Clinical Research within the Faculty of Medicine at the RWTH Aachen University.
Abstract (Originalsprache)
The majority of drugs are typically orally administered. The journey from drug discovery to approval is often long and expensive, involving multiple stages. A major challenge in the drug development process is drug-induced liver injury (DILI), a condition that affects the liver, the organ responsible for metabolizing most drugs. Traditionally, identifying DILI risk has been difficult due to the poor correlation between preclinical animal models and in vitro systems. Differences in physiology between humans and animals or cell lines contribute to the failure of many drug programs during clinical trials. The use of advanced in vitro systems that closely mimic human physiology, such as organ-on-a-chip models like gut–liver-on-a-chip, can be crucial in improving drug efficacy while minimizing toxicity. Additionally, the adaptation of these technologies has the potential to significantly reduce both the time and cost associated with obtaining safe drug approvals, all while adhering to the 3Rs principle (replacement, reduction, refinement). In this review, we discuss the significance, current status, and future prospects of advanced platforms, specifically organ-on-a-chip models, in supporting preclinical drug discovery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital Aachen, D-52074 Aachen, Germany.
- Keliomics Inc., 4640 S Macadam Ave #270, Portland, OR 97239, USA.
ORCID-Profile: Dileep G Nair, Ralf Weiskirchen
Förderung
- German Research Foundation
- Deutsche Krebshilfe
- Interdisciplinary Centre for Clinical Research within the Faculty of Medicine at the RWTH Aachen University
- RWTH Aachen University
Zitieren
APA
Nair, D. G., & Weiskirchen, R. (2024). Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects. Current Issues in Molecular Biology, 47(1), 7. https://doi.org/10.3390/cimb47010007
Vancouver
Nair DG, Weiskirchen R. Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects. Current Issues in Molecular Biology. 2024;47(1):7. doi:10.3390/cimb47010007
BibTeX
@article{Nair2024,
author = {Nair, Dileep G and Weiskirchen, Ralf},
title = {Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects},
journal = {Current Issues in Molecular Biology},
year = {2024},
volume = {47},
number = {1},
pages = {7},
doi = {10.3390/cimb47010007}
}
EUVIMED